A phase IIa study of the anti-PD-L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL-T trial.
Peripheral T-cell lymphomas (PTCL) are rare chemoresistant malignancies with poor outcomes, necessitating novel therapies. The programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1) axis is frequently overexpressed in PTCL and represents a potential therapeutic target; however, PD-L1 inhibition has not been explor...